Document Detail


Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin.
MedLine Citation:
PMID:  2117499     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
STUDY OBJECTIVE: The aim of the study was to test the hypothesis that platelet serotonin 5HT2 receptors are important in the genesis of thrombosis in stenosed coronary arteries. DESIGN: The specific serotonin 5HT2 receptor antagonist, ritanserin was used as a pharmacological tool to examine the effect of removal of the participation of the 5HT2 receptors on thrombus growth, in a paired statistical design. EXPERIMENTAL MATERIAL: The study involved 10 open chest anaesthetised dogs, with constrictors of critical diameter applied to the left circumflex coronary artery. MEASUREMENTS AND MAIN RESULTS: Blood flow was monitored in the left circumflex coronary arteries, distal to the critical stenosis. Flow reductions occurred that have previously been shown to be caused by the accumulation of platelet thrombi. By embolising the thrombi, the process could be monitored cyclically (cyclic flow reductions). The specific serotonin 5HT2 receptor antagonist, ritanserin, abolished cyclic flow reductions at a dose of 0.5 mg.kg-1. There was no effect on blood pressure or heart rate on administration of ritanserin at any dose. The serotonin blockade by ritanserin also prevented the reestablishment of cyclic flow reductions by adrenaline infusion (0.4 micrograms.kg-1.min-1), but required ritanserin doses up to 1.5 mg.kg-1. Ex vivo aggregation of platelets was reduced in blood taken from the dogs after ritanserin administration. CONCLUSIONS: These results constitute further evidence of the possible importance of serotonin as a mediator of platelet thrombosis in stenosed coronary arteries.
Authors:
S Torr; M I Noble; J D Folts
Related Documents :
15294409 - Effects of vasopressin on left anterior descending coronary artery blood flow during ex...
650909 - Prostaglandin e2 and epinephrine participate in cyclical reduction of coronary blood pr...
17574929 - Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variatio...
16987589 - Microvascular blood flow during cardiopulmonary resuscitation is predictive of outcome.
816659 - Effect of propranolol and nitroglycerin on hemoglobin--oxygen affinity.
19699859 - Systematic review of studies of the effect of hyperoxia on coronary blood flow.
6363319 - Acute post-irradiation canine intestinal blood flow.
16830959 - Clinical laboratory measurement of serum, plasma, and blood viscosity.
16822799 - Duplex ultrasound of the superior mesenteric artery in chronic pancreatitis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cardiovascular research     Volume:  24     ISSN:  0008-6363     ISO Abbreviation:  Cardiovasc. Res.     Publication Date:  1990 Jun 
Date Detail:
Created Date:  1990-09-27     Completed Date:  1990-09-27     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  0077427     Medline TA:  Cardiovasc Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  465-70     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Wisconsin Hospital and Clinics, Madison.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Coronary Disease / complications*,  prevention & control*
Coronary Thrombosis / etiology,  prevention & control*
Dogs
Dose-Response Relationship, Drug
Epinephrine / pharmacology
Female
Male
Piperidines / therapeutic use*
Platelet Aggregation / drug effects
Platelet Aggregation Inhibitors
Receptors, Serotonin / drug effects
Ritanserin
Serotonin Antagonists / therapeutic use*
Grant Support
ID/Acronym/Agency:
P01-HL29586-7/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Piperidines; 0/Platelet Aggregation Inhibitors; 0/Receptors, Serotonin; 0/Serotonin Antagonists; 51-43-4/Epinephrine; 87051-43-2/Ritanserin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Initial experience with a universal-length copolymer ureteral stent.
Next Document:  Trans-activation by HIV-1 Tat via a heterologous RNA binding protein.